Safety of Intravenous Push Valproate Compared with Intravenous Piggyback at a Tertiary Academic Medical Center.
- Published in:
- Clinical Drug Investigation, 2024, v. 44, n. 3, p. 175, doi. 10.1007/s40261-024-01349-z
- By:
- Publication type:
- Article
Works matching IS 11732563 AND DT 2024 AND VI 44 AND IP 3
Results: 8
1
2
Safety and Efficacy of Biologic Medications and Janus Kinase Inhibitors in Patients with Down Syndrome: A Retrospective Cohort Study.
- Published in:
- Clinical Drug Investigation, 2024, v. 44, n. 3, p. 219, doi. 10.1007/s40261-024-01348-0
- By:
- Publication type:
- Article
3
Thromboembolic Events Associated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Pharmacovigilance Analysis of the US FDA Adverse Event Reporting System (FAERS) Database.
- Published in:
- Clinical Drug Investigation, 2024, v. 44, n. 3, p. 199, doi. 10.1007/s40261-024-01346-2
- By:
- Publication type:
- Article
4
Cost-Effectiveness Evaluation of Oral CGRP Antagonists, Atogepant and Rimegepant, for the Preventative Treatment of Episodic Migraine: Results from a US Societal Perspective Model.
- Published in:
- Clinical Drug Investigation, 2024, v. 44, n. 3, p. 209, doi. 10.1007/s40261-024-01345-3
- By:
- Publication type:
- Article
5
Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19: Evidence from the US National COVID Cohort Collaborative (N3C).
- Published in:
- Clinical Drug Investigation, 2024, v. 44, n. 3, p. 183, doi. 10.1007/s40261-024-01344-4
- By:
- Publication type:
- Article
6
Cost-Effectiveness Analysis of Camrelizumab Plus Rivoceranib Versus Sorafenib as a First-Line Therapy for Unresectable Hepatocellular Carcinoma in the Chinese Health Care System.
- Published in:
- Clinical Drug Investigation, 2024, v. 44, n. 3, p. 149, doi. 10.1007/s40261-024-01343-5
- By:
- Publication type:
- Article
7
Effect of Ticagrelor versus Clopidogrel on All-Cause and Cardiovascular Mortality in Acute Coronary Syndrome Patients with Hyperuricemia.
- Published in:
- Clinical Drug Investigation, 2024, v. 44, n. 3, p. 163, doi. 10.1007/s40261-024-01342-6
- By:
- Publication type:
- Article
8
Forty-Eight-Month Monitoring of Disease Activity in Patients with Long-Standing Rheumatoid Arthritis Treated with TNF-α Inhibitors: Time for Clinical Outcome Prediction and Biosimilar vs Biologic Originator Performance.
- Published in:
- Clinical Drug Investigation, 2024, v. 44, n. 3, p. 141, doi. 10.1007/s40261-024-01341-7
- By:
- Publication type:
- Article